PBA
OCUL icon

Paradigm Biocapital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Paradigm Biocapital Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,935,284
Closed -$35.6M – 39
2025
Q4 		$35.6M Sell
2,935,284
-562,023
-16% -$6.83M 0.91% 23
2025
Q3 		$40.9M Buy
3,497,307
+76,967
+2% +$920K 1.16% 24
2025
Q2 		$31.7M Buy
3,420,340
+2,106,322
+160% +$16.5M 1.36% 21
2025
Q1 		$9.63M Buy
+1,314,018
New +$10.1M 0.44% 27

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Paradigm Biocapital Advisors's OCUL Position: Q1 2026 in Review

Paradigm Biocapital Advisors sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 2,935,284 shares — an estimated $35.6M sold.

Paradigm Biocapital Advisors first reported a position in OCUL in Q1 2025 and held it in 4 quarters. The position peaked at $40.9M in Q3 2025. 270 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Paradigm Biocapital Advisors reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,935,284 Ocular Therapeutix shares in Q1 2026, an estimated $35.6M.
  • Paradigm Biocapital Advisors first reported a position in Ocular Therapeutix in Q1 2025 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's Ocular Therapeutix position peaked at $40.9M in Q3 2025.
  • 270 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.